Trial reportPsychopharmacology2012
Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence.
Trial report in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.Journal of psychiatry & neuroscience : JPN · 2018Trial
- Putting the brakes on the "drive to eat": Pilot effects of naltrexone and reward-based eating on food cravings among obese women.Eating behaviors · 2015Trial
- Trial
- Does the Neuroimmune Modulator Ibudilast Alter Food Craving? Results in a Sample With Alcohol Use Disorder.Journal of addiction medicineTrial
- Long-Acting Naltrexone Restores Network Connectivity in Subjects With Comorbid Cannabis and Opioid Use Disorder.Addiction biology · 2026Article
- Long-acting naltrexone restores network connectivity in subjects with co-morbid cannabis and opioid use disorder.bioRxiv : the preprint server for biology · 2025Article
- Metabolic profiles associated with opioid use and opioid use disorder: a narrative review of the literature.Current addiction reports · 2023Article
- Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence.Frontiers in psychiatry · 2023Article
- Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.Drug and alcohol dependence · 2021Article
- Associations between opioid dependence and sweet taste preference.Psychopharmacology · 2021Article
- Aberrant Feeding and Growth in Neonates With Prenatal Opioid Exposure: Evidence of Neuromodulation and Behavioral Changes.Frontiers in pediatrics · 2021Review
- Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.Scientific reports · 2020Article
- α5GABAPsychopharmacology · 2019Article
- Neuroimaging of reward mechanisms in Gambling disorder: an integrative review.Molecular psychiatry · 2019Review
- Opioid system and human emotions.British journal of pharmacology · 2018Review
- Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder.Journal of substance abuse treatment · 2018Article
- Feeding Releases Endogenous Opioids in Humans.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Naltrexone alters the processing of social and emotional stimuli in healthy adults.Social neuroscience · 2016Article
- Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior.Current neuropharmacology · 2016Review
- Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.Translational psychiatry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundOpioid neurotransmission mediates hedonic value of sweet tastants; their intake may be exaggerated by the consumption of exogenous opioids (e.g., opioid dependence). Sweet Taste Test (STT) is a validated quantitative instrument assessing taste perception and hedonic features of sugar (sucrose) using a randomized and double-blind administration at five different sucrose concentrations ranging from 0.05 to 0.83 M.
methodsThe STT and cue-induced craving procedure were administered to opioid-dependent patients (n = 15) before and 1 week after the injection of a long-acting depot naltrexone (XRNT) preparation.
resultsAnalyses of covariance, employing sucrose concentration and its perceived taste as covariates, showed that XRNT therapy significantly reduced the self-reported hedonic and motivational characteristics of sucrose. Greater reductions in both these characteristics were associated with more diminution in the cue-induced opioid craving.
conclusionsOpioid antagonism in opioid-dependent subjects leads to a smaller sweet taste reward, which, in turn, may be proportional to decreased opioid craving. These pilot results support the heuristic value of the STT as a potential marker of the XRNT treatment response and call for further inquiry into potential clinical applications of the test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.